ProteanFect™ achieves high transfection efficiency with DNA/mRNA in Jurkat T cells
ProteanFect™ demonstrates superior transfection efficiency for both EGFP pDNA and mRNA in Jurkat T cells compared to Lipofectamine 3000 and MessengerMAX. It achieves significantly higher fluorescence intensity and frequency, underscoring its enhanced delivery capability and optimized expression performance in these challenging immune cells.
ProteanFect™ achieves high transfection efficiency of high molecular weight nucleic acids or co-transfection of multiple nucleic acids in Jurkat T cells
ProteanFect™ demonstrates robust transfection efficiency in K562 cells, as evidenced by a significant increase in EGFP-positive cells post-transfection, achieving a 50.7% expression rate. Additionally, it effectively mediates gene knockdown, with target-siRNA reducing gene expression by 64% at 24 hours and 72% at 48 hours, normalized to GAPDH.
ProteanFect™ achieves high transfection efficiency in K562 cells
ProteanFect™ demonstrates robust transfection efficiency in K562 cells, as evidenced by a significant increase in EGFP-positive cells post-transfection, achieving a 50.7% expression rate. Additionally, it effectively mediates gene knockdown, with target-siRNA reducing gene expression by 64% at 24 hours and 72% at 48 hours, normalized to GAPDH.